The Ancient Drug Salicylate Indirectly Targets Fructose‐1,6‐Bisphosphatase to Suppress Liver Glucose Production in Diet‐Induced Obese Mice
Acta Physiologica · 2025
DOI: 10.1111/apha.70058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Physiologica, 2025. Verfasst von Raid B Nisr und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetes, Endocrinology and Reproductive Biology, School of Medicine, University of Dundee, Dundee, UK. Hauptthemen laut MEDLINE: Fructose-Bisphosphatase, Salicylates, Liver, Obesity. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Academy of Medical Sciences, British Heart Foundation.
Abstract (Originalsprache)
Aims
The benefit of salicylate in the treatment of diabetes has been recognized for over a century; however, challenging side effects have prevented widespread use. A better understanding of the relevant enzyme targets mediating its anti‐hyperglycaemic effect may lead to the development of novel therapies for diabetes. Here, we investigated the contribution of 5′‐adenosine monophosphate ( AMP )‐dependent inhibition of fructose‐1,6‐bisphosphatase 1 ( FBP1 ) to the anti‐hyperglycaemic action of salicylate.
Methods
We studied AMP ‐insensitive FBP1 G27P knockin ( KI ) mice through a variety of cellular approaches, including proteomics, Seahorse metabolic analysis, glucose production, and other assays, in addition to a detailed assessment of metabolic responses in vivo.
Results
Compared with wild‐type littermates, AMP ‐insensitive FBP1 KI mice were resistant to the effects of the drug on body weight, glucose tolerance, pyruvate disposal, liver lipid content and hepatic glucose production. Compared with wild‐type, KI hepatocytes exhibited baseline differences in glycolytic, TCA cycle and fatty acid oxidation enzyme levels, potentially linking gluconeogenic dysregulation and its reversal to non‐carbohydrate fuel management.
Conclusion
Collectively, our data highlight a novel mechanism of action for the effects of salicylate on glycaemia and weight gain, which depends on AMP‐mediated allosteric inhibition of FBP1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Diabetes, Endocrinology and Reproductive Biology, School of Medicine, University of Dundee, Dundee, UK.
- Centre for Advanced Scientific Technologies, School of Life Sciences, University of Dundee, Dundee, UK.
- Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Graham Rena
Förderung
- Medical Research Council
- Academy of Medical Sciences
- British Heart Foundation
- Diabetes UK
- Novo Nordisk Foundation
- Novo Nordisk Fonden
Zitieren
APA
Nisr, R. B., Atrih, A., Lara, E. J. G., Lamont, D., Luda, K. M., McCrimmon, R. J., Sakamoto, K., Rena, G., & McNeilly, A. D. (2025). The Ancient Drug Salicylate Indirectly Targets Fructose‐1,6‐Bisphosphatase to Suppress Liver Glucose Production in Diet‐Induced Obese Mice. Acta Physiologica. https://doi.org/10.1111/apha.70058
Vancouver
Nisr RB, Atrih A, Lara EJG, Lamont D, Luda KM, McCrimmon RJ, et al. The Ancient Drug Salicylate Indirectly Targets Fructose‐1,6‐Bisphosphatase to Suppress Liver Glucose Production in Diet‐Induced Obese Mice. Acta Physiologica. 2025. doi:10.1111/apha.70058
BibTeX
@article{Nisr2025,
author = {Nisr, Raid B and Atrih, Abdelmadjid and Lara, Erika J Gutierrez and Lamont, Douglas and Luda, Katarzyna M and McCrimmon, Rory J and Sakamoto, Kei and Rena, Graham and McNeilly, Alison D},
title = {The Ancient Drug Salicylate Indirectly Targets Fructose‐1,6‐Bisphosphatase to Suppress Liver Glucose Production in Diet‐Induced Obese Mice},
journal = {Acta Physiologica},
year = {2025},
doi = {10.1111/apha.70058}
}
EUVIMED